Evolution of a regulatory framework for pharmaceuticals derived from genetically modified plants
Related Experiment Video
Updated: Jul 3, 2026

Preventing the Spread of Malaria and Dengue Fever Using Genetically Modified Mosquitoes
Published on: July 4, 2007
Armin Spök1, Richard M Twyman, Rainer Fischer
1Inter-University Research Centre for Technology, Work and Culture (IFZ), Schlögelgasse 2, A-8010 Graz, Austria.
Abstract:
The use of genetically modified (GM) plants to synthesize proteins that are subsequently processed, regulated and sold as pharmaceuticals challenges two very different established regulatory frameworks, one concerning GM plants and the other covering the development of biotechnology-derived drugs. Within these regulatory systems, specific regulations and guidelines for plant-made pharmaceuticals (PMPs)--also referred to as plant-derived pharmaceuticals (PDPs)--are still evolving. The products nearing commercial viability will ultimately help to road test and fine-tune these regulations, and might help to reduce regulatory uncertainties. In this review, we summarize the current state of regulations in different countries, discuss recent changes and highlight the need for further regulatory development in this burgeoning, new industry. We also make the case for the harmonization of international regulations.
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Transgenic Plants
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
What is Genetic Engineering?
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

